Targeted atherosclerosis treatment
AssigneeBarnes-Jewish Hospital
InventorsGregory M. Lanza, Samuel A. Wickline
Life of this patent
Estimating the term…
Abstract
This invention relates generally to methods for ameliorating at least one symptom or aspect of atherosclerosis. The methods include administration of targeted carrier compositions comprising a therapeutic agent effective in ameliorating at least one aspect of atherosclerosis coupled to a targeting ligand effective is targeting the therapeutic agent to tissue associated with atherosclerotic plaque.
Claims6
A method for inhibiting atherosclerotic plaques in a subject which method comprises administering to a subject diagnosed with atherosclerosis, a composition comprising a nanoparticulate carrier contained in an emulsion and an αvβ3 targeting ligand and an anti-angiogenic agent, wherein the targeting ligand and anti-angiogenic agent are coupled through colocalization in said nanoparticles;
- and
- wherein the anti-angiogenic agent is fumagillin, TNP470 or rapamycin,
- wherein said anti-angiogenic agent is effective at a dosage at least 56,000 fold lower than that required when said anti-angiogenic agent is administered as a free drug.
Dependencies are inferred from the claim text.